切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2022, Vol. 16 ›› Issue (03) : 160 -166. doi: 10.3877/cma.j.issn.1674-0807.2022.03.005

论著

吡咯替尼新辅助治疗人表皮生长因子受体2阳性乳腺癌疗效及安全性的Meta分析
杨森果1, 杨海松1,†(), 张世泳1, 任宇1, 李秋德2, 张馨1, 李红1   
  1. 1. 550000　贵阳，贵州医科大学附属医院乳腺外科
    2. 550000　贵阳，贵州医科大学附属医院生物与工程学院
  • 收稿日期:2022-02-28 出版日期:2022-06-01
  • 通信作者: 杨海松
  • 基金资助:
    国家自然科学基金地区项目资助(62166009); 贵州省卫生健康委员会科学技术基金项目资助(gzwkj2022-084)

Efficacy and safety of pyrotinib in neoadjuvant therapy of HER-2-positive breast cancer: a meta-analysis

Senguo Yang1, Haisong Yang1,†(), Shiyong Zhang1, Yu Ren1, Qiude Li2, Xin Zhang1, Hong Li1   

  1. 1. Department of Breast Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang 550000, China
    2. College of Biology and Engineering, Guizhou Medical University, Guiyang 550000, China
  • Received:2022-02-28 Published:2022-06-01
  • Corresponding author: Haisong Yang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

杨森果, 杨海松, 张世泳, 任宇, 李秋德, 张馨, 李红. 吡咯替尼新辅助治疗人表皮生长因子受体2阳性乳腺癌疗效及安全性的Meta分析[J]. 中华乳腺病杂志(电子版), 2022, 16(03): 160-166.

Senguo Yang, Haisong Yang, Shiyong Zhang, Yu Ren, Qiude Li, Xin Zhang, Hong Li. Efficacy and safety of pyrotinib in neoadjuvant therapy of HER-2-positive breast cancer: a meta-analysis[J]. Chinese Journal of Breast Disease(Electronic Edition), 2022, 16(03): 160-166.

目的

评估吡咯替尼联合新辅助化疗治疗HER-2阳性早期或局部晚期乳腺癌的疗效及安全性。

方法

检索中国知网、万方、维普、中国生物医学文献服务系统(SinoMed)及PubMed、Embase、Cochrane Library等数据库中吡咯替尼治疗HER-2阳性早期或局部晚期乳腺癌的随机对照研究，检索年限为建库以来至2022年2月9日，文献质量按照Cochrane Review Handbook 5.1.0进行评分，提取指标包括客观反应率、总病理完全缓解率、腹泻等不良事件发生率。对符合质量评价标准的研究使用RevMan 5.4.1软件进行数据提取及定量合成，并根据其异质性大小分别采用固定效应模型或随机效应模型的方法进行分析。

结果

最终纳入4项研究，共554例患者，其中吡咯替尼联合化疗组278例，单用化疗组276例。Meta分析结果显示，吡咯替尼联合化疗较单用化疗能明显提高患者的客观反应率(RR＝1.15，95%CI：1.07~1.24，P<0.001)和总病理完全缓解率(RR＝1.90，95%CI：1.45~2.50，P<0.001)。不良反应方面，吡咯替尼联合化疗组≥3级腹泻发生率及任何级别腹泻事件发生率均明显升高(RR＝7.67，95%CI：4.38~13.45，P<0.001；RR＝5.62，95%CI：3.95~8.00，P<0.001)；而2组患者白细胞减少、血小板减少、恶心/呕吐以及手足综合征发生率的差异均无统计学意义(RR＝1.02，95%CI：0.87~1.21，P＝0.790；RR＝1.00，95%CI：0.70~1.43，P＝0.990；RR＝1.30，95%CI：1.00~1.68，P＝0.050；RR＝1.46，95%CI：0.75~2.86，P＝0.270)。

结论

针对早期或局部晚期HER-2阳性乳腺癌患者，吡咯替尼联合化疗的新辅助治疗方案能够明显提高其客观反应率及总病理完全缓解率，但同时也增加患者≥3级腹泻的发生风险。在临床实践中需重视对腹泻等不良事件的管理，以保证患者治疗的顺利进行及提高其生活质量。

关键词: 吡咯替尼, 乳腺肿瘤, 新辅助治疗, 治疗结果, 安全
Objective

To evaluate the efficacy and safety of pyrotinib in the neoadjuvant therapy of HER-2-positive early or locally advanced breast cancer.

Methods

The databases including China National Knowledge Infrastructure(CNKI), Wanfang Data, VIP Med Online, SinoMed, PubMed, Embase and Cochrane Library were searched for the literatures on pyrotinib in the neoadjuvant therapy of HER-2-positive early or locally advanced breast cancer. The retrieval period was from the establishment of the database to February 9, 2022. The quality of the research was assessed according to the Cochrane Review Handbook 5.1.0. The objective response rate, total pCR rate and incidence of adverse events (such as diarrhea) were parameters to be extracted from the literature. Revman 5.4.1 software was used for data extraction and quantitative synthesis in the studies that met the quality assessment criteria. Random effect model or fixed effect model was utilized depending on the heterogeneity.

Results

Four trials were enrolled, including 554 patients. Totally 278 patients received pyrotinib combined with chemotherapy and 276 patients received chemotherapy alone. The results of meta-analysis revealed that compared with chemotherapy alone, pyrotinib combined with chemotherapy significantly improved the objective response rate (RR=1.15, 95%CI: 1.07-1.24, P<0.001) and total pCR rate(RR=1.90, 95%CI: 1.45-2.50, P<0.001). As for adverse events, the incidence of grade 3 or above diarrhea (RR=7.67, 95%CI: 4.38-13.45, P<0.001) and the incidence of diarrhea of any grade(RR=5.62, 95%CI: 3.95-8.00, P<0.001) in combined therapy group were significantly increased compared with chemotherapy, but there was no significant difference in the incidence of leucopenia (RR=1.02, 95%CI: 0.87-1.21, P=0.790), thrombocytopenia (RR=1.00, 95%CI: 0.70-1.43, P=0.990), nausea/vomiting(RR=1.30, 95%CI: 1.00-1.68, P=0.050) and hand-foot syndrome(RR=1.46, 95%CI: 0.75-2.86, P=0.270) between two groups.

Conclusions

For patients with HER-2-positive early or locally advanced breast cancer, the neoadjuvant regimen of pyrotinib combined with chemotherapy can significantly improve the objective response rate and total pCR rate, and increase the risk of grade 3 or above diarrhea. In clinical practice, attention should be paid to the management of adverse events such as diarrhea, so as to ensure the efficacy and improve the quality of life.

Key words: Pyrotinib, Breast neoplasms, Neoadjuvant therapy, Treatment outcome, Safety
图1 吡咯替尼新辅助治疗人表皮生长因子受体2阳性乳腺癌患者的文献筛选流程
图2 纳入的吡咯替尼新辅助治疗人表皮生长因子受体2阳性乳腺癌研究质量评价 注：1代表Ding等[12]的研究；2代表Li等[13]的研究；3代表郑等[14]的研究；4代表Wu等[15]的研究；代表偏倚风险低；代表偏倚风险高；代表偏倚风险不明确
表1 吡咯替尼新辅助治疗人表皮生长因子受体2阳性乳腺癌研究中患者的基本特征
研究者 年份 试验组/对照组措施 例数 年龄[岁，±s或M(P25，P75) ] 结局指标 ORR(%) tpCR率(%) ≥3级腹泻发生率(%)
Ding等[12] 2021年 TCbH+P/TCbH 21 未提供a tpCR、ORR、腹泻发生率 100 71.4 28.6
      30     83.3 36.7 10.0
Li等[13] 2021年 TCbH+P/TCbH 63 未提供b tpCR、ORR、腹泻发生率等 100 75.0 11.1
      53     75.0 25.0 0
郑向欣等[14] 2021年 TCbH+P/TCbH 16 31.7±3.5 tpCR、ORR、腹泻发生率等 100 43.8 18.8
      16 32.4±3.9   75.0 25.0 0
Wu等[15] 2021年 TH+P/TH 178 50(43，55) tpCR、ORR、腹泻发生率等 91.6 41.0 44.4
      177 50(44，55)   81.9 22.0 5.1
图3 吡咯替尼新辅助治疗人表皮生长因子受体2阳性乳腺癌患者的客观反应率森林图
图4 吡咯替尼新辅助治疗人表皮生长因子受体2阳性乳腺癌患者的总病理完全缓解率森林图
图5 吡咯替尼新辅助治疗人表皮生长因子受体2阳性乳腺癌患者的≥3级腹泻发生率森林图
表2 吡咯替尼新辅助治疗人表皮生长因子受体2阳性乳腺癌患者后出现的相关不良反应
不良反应 RR值 95%CI P值
腹泻 5.62 3.95~8.00 <0.001
白细胞减低 1.02 0.87~1.21 0.790
血小板减低 1.00 0.70~1.43 0.990
恶心/呕吐 1.30 1.00~1.68 0.050
手足综合征 1.46 0.75~2.86 0.270
图6 吡咯替尼新辅助治疗人表皮生长因子受体2阳性乳腺癌患者的研究发表偏倚漏斗图 注：RR为相对危险度
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021, 71(3): 209-249.
[2]
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. Arch Pathol Lab Med, 2014, 138(2): 241-256.
[3]
Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987, 235(4785): 177-182.
[4]
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27[J]．J Clin Oncol，2008，26(5): 778-785.
[5]
Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study[J]. J Clin Oncol，2019，37(25): 2206-2216.
[6]
Gianni L，Pienkowski T，Im YH，et al.5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced，inflammatory, or early-stage HER-2-positive breast cancer (NeoSphere)：a multicentre，open-label，phase 2 randomised trial[J]．Lancet Oncol, 2016，17(6)：791-800.
[7]
Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER-2-positive metastatic breast cancer (PHOEBE)：a multicentre，open-label，randomised，controlled，phase 3 trial[J]．Lancet Oncol，2021，22(3): 351-360.
[8]
Yan M, Bian L, Hu X, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study[J]. Transl Breast Cancer Res, 2020, 1: 13.
[9]
李雪迎. Meta分析研究设计中的PICOS原则[J]. 中国介入心脏病学杂志，2016, 24(11): 611.
[10]
Higgins JPT，Green S. Cochranehandbook for systematic reviews of interventions. Version 5.1.0[updated March 2011][EB/OL]．[2022-02-10]．

URL    
[11]
梁万年，刘民，陈峰，等．医学科研方法学[M].2版．北京：人民卫生出版社，2014：162-177.
[12]
Ding X, Mo W, Xie X, et al. Pyrotinib as neoadjuvant therapy for HER-2+ breast cancer: A multicenter, randomized, controlled, phase Ⅱ trial [EB/OL]．[2022-02-10]．

URL    
[13]
Li Q，Wang Y，Zhu M，et al. Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER-2-positive breast cancer: a cohort study[J]．Gland Surg，2021，10(12): 3389-3402.
[14]
郑向欣，张旭旭，吴骥，等．吡咯替尼联合TCbH方案治疗首诊局部晚期HER-2阳性年轻乳腺癌患者的疗效及安全性[J]．中国普通外科杂志，2021, 30(11)：1304-1310.
[15]
Wu J, Liu Z, Yang H, et al. 2021 SABCS abstracts. PD8-08: Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER-2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study[EB/OL]．[2022-02-10]．

URL    
[16]
中国抗癌协会乳腺癌专业委员会．中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志，2021, 31(10)：954-1040.
[17]
Gianni L，Pienkowski T，Im YH，et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced，inflammatory，or early HER-2-positive breast cancer (NeoSphere)：a randomised multicentre，open-label，phase 2 trial[J]．Lancet Oncol，2012，13(1): 25-32.
[18]
Shao Z，Pang D，Yang H，et al. Efficacy，safety，and tolerability of pertuzumab，trastuzumab，and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia：the PEONY phase 3 randomized clinical trial[J]．JAMA Oncol，2020，6(3)：e193692.
[19]
Baselga J，Bradbury I，Eidtmann H，et al. Lapatinib with trastuzumab for HER-2-positive early breast cancer(NeoALTTO)：a randomised，open-label，multicentre，phase 3 trial[J]．Lancet，2012, 379(9816)：633-640.
[20]
Robidoux A，Tang G，Rastogi P，et al. Lapatinib as a component of neoadjuvant therapy for HER-2-positive operable breast cancer (NSABP protocol B-41)：an open-label，randomised phase 3 trial[J]．Lancet Oncol，2013，14(12)：1183-1192.
[21]
Liu Z, Wang C, Chen X, et al. Pathological response and predictive role of tumour-infiltrating lymphocytes in HER-2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy(Panphila)：a multicentre phase 2 trial[J]．Eur J Cancer，2022, 165：157-168.
[22]
Xuhong J，Qi X，Tang P，et al. Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for stage Ⅰ-Ⅲ HER-2-positive breast cancer: a phase Ⅱ clinical trial[J]．Oncologist，2020，25(12): e1909-e1920.
[1] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 844-848.
[2] 唐玮, 何融泉, 黄素宁. 深度学习在乳腺癌影像诊疗和预后预测中的应用[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 323-328.
[3] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[4] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[5] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[6] 伍秋苑, 陈佩贤, 邓裕华, 何添成, 周丹. 肠道微生物在乳腺癌中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 362-365.
[7] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[8] 周婉丽, 钱铮, 李喆. 槐耳在乳腺癌免疫治疗中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 369-371.
[9] 熊倩, 罗凤. 乳腺癌患者术后康复现状与对策的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 372-374.
[10] 杨小菁, 姜瑞瑞, 石玉香, 王静静, 李长天. 乳腺孤立性纤维性肿瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 375-377.
[11] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[12] 李智铭, 郭晨明, 庄晓晨, 候雪琴, 高军喜. 早期乳腺癌超声造影定性及定量指标的对比研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 639-643.
[13] 张海涛, 康婵娟, 翟静洁. 胰管支架置入治疗急性胆源性胰腺炎效果观察[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 654-657.
[14] 汤海琴, 郭秀枝, 朱晓素, 赵世娣. “隧道法”腹腔镜解剖性左半肝切除术的临床安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 674-677.
[15] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号